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BACKGROUND: The coexistence of familial adenomatous 
polyposis and spondyloarthritis is rarely defined in literature. The 
primary aim of this presentation is to report a development of 
peripheral arthritis in 3 years following colon surgery with the 
diagnosis of familial adenomatous polyposis (FAP). The secondary 
aim is to discuss the challenge of in treatment of refractory 
arthritis, which needs to be treated with biologics. However, it is 
not yet known well about their safety on patients who have risks for 
cancer development.  
CASE DETAILS: A 25-year-old female patient was admitted to the 
rheumotology outpatient clinic. The patient had undergone total 
colectomy and ileoanal anastomosis because of FAP three years 
ago. On her physical examination, there was arthritis on her left 
ankle and enthesitis on both Achilles tendons.   
CONCLUSION: This case report presents a 25-year-old female 
patient with Ankylosing spondylitis (AS) and FAP whose treatment 
with biologics is critical due to the risk of cancer development due 
FAP. Although the potential risk of development of malignancies 
with TNF-blocking therapy seems to be no more than TNF-naïve 
patients and general population. But the safety of these drugs on 
patients with risks for cancer development is still unknown. 
KEYWORDS: Spondyloarthtritis, familial adenomatous polyposis, 
nonsteroid anti-inflammatory drugs, disease modifying anti-





Spondyloarthritis (SpA) are a group of different inflammatory 
diseases which share common clinical and genetic features, such as 
involvement of the axial skeletons (sacroiliac joints and spine), 
certain patterns of the peripheral joint involvements, presence of 
enthesitis and/or dactylitis, characteristic extra-articular 
manifestations (acute anterior uveitis, psoriasis, inflammatory bowel 
disease) and association with the presence of HLA-B27 (1).   
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Based on recommendations developed by ASAS, 
ACR (American College of Rheumatology) and 
EULAR (European League Against Rheumatism), 
the treatment of SpA consists of non-
pharmacological and pharmacological methods. 
Pharmacological treatment methods can be listed 
as follows; nonsteroidal anti-inflammatory drugs 
(NSAIDs), conventional disease-modifying anti-
rheumatic drugs (cDMARDs) and biologic agents 
(2). 
Familial adenomatous polyposis (FAP) is an 
autosomal dominant disorder characterized by 
hundreds of colorectal adenomatous polyps that 
progress to colorectal cancer (CRC). Nearly fifty 
percent of patients develop adenomas by the age 
of 15 and 95% of them by the age of 35. Since 
patients who had been diagnosed with FAP have 
risk for cancer development, prophylactic 





A 25-year-old female patient with pain in the low 
back area, the right hip joint, both wrists, the 
ankles, all the small joints of hands and the feet, 
and also swelling of the left ankle was admitted to 
the rheumatology outpatient clinic. The pain in the 
low back and right hip joint started two years ago 
without any trauma. The patient claimed that she 
had night pain and morning stiffness lasting one 
hour every day for two years. She had undergone 
total colectomy and ileo-anal anastomosis because 
of FAP three years ago. In her family, colon 
cancer was present in her father, her aunt and her 
grandfather, and one of the members of her distant 
relatives was diagnosed with ankylosing 
spondylitis. 
On her physical examination, she had pain 
while pressing on her right wrist, both hands and 
the feet metacarpophalangeal and the 
metatarsophalangeal joints and the left ankle. 
There was arthritis on her left ankle and enthesitis 
on both Achilles tendons.   
HLA typing was positive for B27.  
Laboratory analysis revealed C-reactive protein, 
7.8 mg/dl (normal <0.5 mg/dl), and erythrocyte 
sedimentation rate of 83 mm/h as high. 
Hemoglobin was 10.5 g/dl, white blood cell was 
12.36, and platelet count was 481.000/mm3. The 
blood chemistries were all within normal limits. 
The serological tests for HIV and hepatitis B and 
C were negative.  Also, the levels of carcinogenic 
(CA) (CA-72.4: 1.37 U/mL, CA-125: 12.2 U/mL, 
CA-15-3: 5.4 U/mL, CA-19-9: 10.0 U/mL) and 
carcinoembryonic antigens (0.0 ng/mL) were 
normal. Chest X-ray showed no specific 
abnormalities, but bilateral grade 2 sacroiliitis was 
detected on her pelvic radiograms. However, 
typical cervical, thorocal and lomber spine 
syndesmophytes were not identified. Magnetic 
resonance imaging (MRI) revealed active bilateral 
sacroiliitis. On her sacroiliac MRI, there was 
subchondral edema. Also, subchondral erosions 
and localized fat depositions were present in the 
subchondral marrow spaces. 
         Her thoracic, renal, abdominal tomographic 
examinations and thyroidal ultrasound imaging 
did not reveal any abnormality. Her mandibular X-
ray graph and her upper gastrointestinal imaging 
with endoscopy were normal as well. On magnetic 
resonance imaging of her left ankle (Image1-3), an 
intense medullar edema on the dorsal 
subcutaneous tissue was detected at the metatarsal 
level.  
She was diagnosed with ankylosing 
spondylitis due to inflammatory back pain, 
sacroiliitis, peripheral arthritis, enthesitis, HLA 
B27 positivity and radiological imaging based on 
the Assessment of SpondyloArthritis International 
Society (ASAS) criteria (4). 
Lumbar Modified Shober was measured as 
5.5 cm. The patient’s Bath AS Disease Activity 
Index (BASDAI), Bath AS Metrology Index 
(BASMI), Bath AS Functional Index (BASFI), 
and Bath AS Radiologic Index (BASRI) were 6, 9, 
4.05, and 2 respectively.  
Medical treatment was started for ankylosing 
spondylitis with indomethacin (25 mg 2x1), 
Sulfasalazine (500 mg 2x2) and prednisolone 
(5mg 1x1) per oral (P.O). Because of no 
improvement in the patient’s disease activity, 
sulfasalazine was stopped and methotrexate 
(MTX) was started with 15 mg per week 
subcutaneously after six months. Good results in 
swelling of joints, lowering levels of ESR and 
CRP were observed following administration of 
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MTX. After a year without any pain and swelling, 
she started having pain on her left shoulder while 
moving the left shoulder, and swelling and 
erythema were detected on her left ankle. We 
wanted to treat the patient with anti-TNF, but we 
could not because the patient had some risks for 
cancer development due to presence of her FAP. 
Anti-TNFs are effective in inducing clinical 
improvement in spondyloarthitis, but authorities 
do not suggest for patients in risk of developing 




This case report presents a 25-year-old female 
patient with AS and FAP whose treatment with 
biologics was critical because of the risk of cancer 
development due to presence of FAP. Based on 
treatment recommendations by ASAS/EULAR 
and ACR, we started treatment with NSAIDs as 
the first line treatment in optimal doses, but there 
was no clinical improvement in her pain and 
arthritis. As sulfasalazine has been used to treat 
patients with SpA for more than 20 years, it could 
be considered for those with prominent peripheral 
arthritis. We added 2000 mg of sulfasalazine P.O, 
but no improvement in disease activity was 
observed in 6 months of administration. Although 
the beneficial effect of methotrexate was not 
certain due to limited trials of this drug, we 
continued with methotrexate 15 mg 
subcutaneously. Unfortunately, no improvement 
was shown in her disease activity after 3 months 
of regular administration of methotrexate.  
Anti-TNF is an effective treatment for 
patients with SpA who are resistant to DMARDs. 
Several studies have proven the efficacy of anti-
TNF drugs in reducing inflammation status and 
improving the quality of life of AS patients with 
no specific superiority in terms of efficacy of one 
over the others. Interestingly, all available anti-
TNFs are effective in inducing a significant 
clinical improvement in a two-week time frame 
(2). TNF plays a crucial role in defending against 
microbial agents. Therefore, when its effects are 
blocked, patients may be at higher risk of 
infections especially in the upper and lower 
airways and urinary tract. Apart from the risk of 
infections, another source of concern is related to 
the possible occurrence of malignancies. Patients 
with autoimmune diseases have an increased risk 
of developing lymphomas when compared with 
the healthy population (6). Caution should be 
taken when considering TNF-blocking therapy for 
patients with a history of malignancy or 
maintenance of treatment for patients who have a 
potential risk in developing malignancy (7). 
Our case has FAP disease, if she were not 
recognized and treated, it was nearly 100% certain 
that the polyps would develop into a colon 
or rectal cancer by the age 40. Other than 
colorectal cancer, multiple malignancies 
associated with FAP are also recognized. Extra-
colonic malignancies also include thyroid cancer 
(2–3%), pancreatic mucinous adenocarcinomas 
(1%), hepatoblastoma (1%) and brain tumors (ie, 
medulloblastoma; <1%). Therefore, patients with 
FAP are more prone to cancer development (8).  
In a recent published literature assessing the 
cancer risk following initiation of TNF inhibitor 
therapy in a very large population of patients with 
SpA, the incidence regarding the individual SpA 
disease subtypes was resulted as 0.9 which was 
similar in both AS and psoriatic arthritis. The 
authors concluded that treatment with TNF 
inhibitors was not associated with increased risks 
of cancer, neither overall nor for the six most 
common cancer types in patients with SpA (9).   
Likewise, in randomized controlled trials, increase 
in the incidence of solid malignancies with anti-
TNF therapy has not been reported in the long-
term observational studies, with the exception of 
an increased risk of non-melanoma skin cancers 
(10).  
In conclusion, the fact that the TNF alpha 
inhibitors have recently been introduced and long-
term side effects are unknown. Although the 
potential risk in development of malignancies with 
TNF-blocking therapy seems to be no more than 
TNF-naïve patients and general population, the 
safety of these drugs on patients with risks of 
cancer development is still unknown. Therefore, 
further studies are obviously needed to gather 
knowledge about the safety of biologic agents to 
formulate an algorithm for the pharmacological 
treatment of patients with history of previous 
malignancy or having a risk for malignancy. 
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